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Abstract: Mitochondria are ubiquitous intracellular organelles found in almost all eukaryotes and
involved in various aspects of cellular life, with a primary role in energy production. The interest in
this organelle has grown stronger with the discovery of their link to various pathologies, including
cancer, aging and neurodegenerative diseases. Indeed, dysfunctional mitochondria cannot provide
the required energy to tissues with a high-energy demand, such as heart, brain and muscles, leading
to a large spectrum of clinical phenotypes. Mitochondrial defects are at the origin of a group of
clinically heterogeneous pathologies, called mitochondrial diseases, with an incidence of 1 in 5000 live
births. Primary mitochondrial diseases are associated with genetic mutations both in nuclear and
mitochondrial DNA (mtDNA), affecting genes involved in every aspect of the organelle function. As
a consequence, it is difficult to find a common cause for mitochondrial diseases and, subsequently, to
offer a precise clinical definition of the pathology. Moreover, the complexity of this condition makes
it challenging to identify possible therapies or drug targets.
Keywords: ATP production; biogenesis of the respiratory chain; mitochondrial disease; mi-tochondrial
electrochemical gradient; mitochondrial potential; mitochondrial proton pumping; mitochondrial
respiratory chain; oxidative phosphorylation; respiratory complex; respiratory supercomplex
1. Mitochondria
1.1. Origin of Mitochondria and Mitochondrial Genome
According to current theories, mitochondria evolved from free-living bacteria and
participated in the origin of eukaryotic cells through a process known as endosymbiosis [1].
The endosymbiotic hypothesis proposes that original anaerobic eukaryotic (modern views
indicate endosymbiosis with a non-eukaryotic archaeon organism) cells engulfed the
primitive mitochondria and established a favorable interaction (although this occurred
after massive negative selection due to gene shuffling) for both the organisms. Indeed,
mitochondria were able to drastically improve the cell energy production, generating
adenosine triphosphate (ATP) through the respiratory chain, while the host cell offered a
safe environment for bacterial proliferation [2].
This theory was supported by the discovery in the 1960s of mitochondrial DNA
(mtDNA) and an independent mitochondrial translation system. Indeed, mitochondria
contain their own genetic material, mtDNA, which maintains the typical features of bac-
terial DNA: it is a circular 16,569-base pairs (bp) double-stranded molecule, does not
contain introns and is polycistronic [3]. In fact, apart from one non-coding region, called
the displacement loop or D-loop, each gene is contiguous to the next one, albeit some
are partly overlapped. Moreover, contrary to nuclear DNA, mtDNA is present in many
copies in the cell, between 100 and 10,000 copies, proportionally to the energy demand
of the specific tissue [3]. Finally, the mtDNA genetic code differs slightly from nuclear
DNA, presenting different codons encoding for tryptophan and methionine and only two
stop codons. This is true in different species, the genetic code being different, for instance,
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between vertebrates and other metazoans, but it is a universal code in plants; this implies
that the change in the genetic code of mtDNA occurred several times during evolution and
it cannot be the primary cause for the maintenance of mtDNA within the organelle.
During evolution, most of the mitochondrial genes were lost or transferred to nuclear
DNA, and today, mtDNA only contains 37 genes: 11 messenger ribonucleic acids mRNAs,
translated to 13 proteins, 2 ribosomal RNAs (rRNAs, 12S and 16S) and 22 tRNAs [4]. The
structure of mtDNA is represented in Figure 1.
1.2. Mitochondrial DNA Mutations
As for nuclear DNA mutations, alterations in mtDNA can have important pathological
consequences. However, because of the differences between mitochondrial and nuclear
DNA, mtDNA inheritance does not follow the canonical mendelian genetics. Firstly, in
sexuate organisms, mtDNA is maternally inherited [5]; therefore, only the mother can
transmit mutant mtDNA to offspring. Secondly, whilst nuclear genes are present in only
two copies per cell, every cell contains multiple copies of mtDNA. These copies can all be
identical in sequence, giving a condition known as homoplasmy. However, inheritance of
mutated copies, replication errors, oxidative stress or inefficient DNA repair can lead to
mtDNA mutations in a percentage of copies, causing heteroplasmy [3]. The proportion of
mutant DNA versus the wild-type variant has a strong impact on the development and the
severity of the pathological phenotypes.
Figure 1. Schematic representation of mitochondrial DNA (mtDNA). Each protein-encoding gene
is indicated with a colored bar and all the genes encoding for subunits of the same complex are
represented with the same color. rRNAs are indicated in yellow and tRNAs in gray. Source: adapted
from Hoffmann and Spengler, 2018 [6].
1.3. Mitochondrial Membranes
Mitochondria are surrounded by two phospholipidic membranes, the outer mitochon-
drial membrane (OMM) and the inner mitochondrial membrane (IMM), which divide the
organelle into two spaces, the matrix and the intermembrane space (IMS) [7]. The two
membranes present significant differences in lipid composition, characteristics and roles of
the transmembrane proteins, permeability and shape and are the result of the endosym-
biotic origin of the organelle. Indeed, the OMM is more similar in lipid composition to
Int. J. Mol. Sci. 2021, 22, 586 3 of 53
eukaryotic cell membranes, while the IMM resembles the cardiolipin-containing bacterial
membranes [2]. The IMM is characterized by a higher protein/lipid ratio and forms highly
packed invaginations in the matrix, called cristae [8]. Embedded in the cristae resides,
together with many other proteins, the oxidative phosphorylation (OXPHOS) machinery
and one proposed reason for the IMM folding is to increase the available surface for energy
production. The part of the IMM that does not protrude in the matrix but, instead, runs
parallel to the OMM is called the inner boundary membrane (IBM). Cristae and the IBM are
connected via narrow tubular or slit-like structures, the cristae junctions (CJs) [9] (Figure 2).
Figure 2. Schematic representation of mitochondrial architecture. The outer mitochondrial membrane
(OMM), inner mitochondrial membrane (IMM), inner boundary membrane (IBM), cristae junctions
(CJ), intermembrane space (IMS), cristae and mitochondrial matrix are indicated.
Moreover, the OMM and IMM differ largely in their permeability. While the OMM
allows the passage of ions and small molecules through voltage-dependent anion channels
(VDACs) [10], only water, oxygen (O2) and carbon dioxide (CO2) can pass freely through
the IMM. This selectivity allows the formation of an electrochemical gradient across the
membrane, which forms the basis for ATP production, and the tight regulation of other
ions concentrations, such as calcium, largely used in cell signaling [11,12].
1.4. Mitochondrial Cristae
Mitochondria are internally organized into cristae, invaginations of the IMM, which
can be dynamically reorganized according to various stimuli, such as changes in energy
requirements or apoptotic signals, becoming more or less compact [13]. The formation
and maintenance of these structures is a complex process that requires the participation
of many proteins, including the mitochondrial contact site and cristae organizing system
(MICOS) and the fusion protein Optic atrophy type 1 (OPA1). The MICOS and OPA1 have
been widely associated with the regulation of the cristae architecture, specifically at the
cristae junction [14].
The MICOS complex was originally characterized and largely studied in yeast, where
it is composed of six subunits: Mic10/MINOS1, Mic12/Aim5, Mic19/CHCHD3, Mic26/
ApoO, Mic27/ApoOL and Mic60/Mitofilin [15]. In mammals, this system is more com-
plicated and two additional subunits have been described: Mic25/CHCHD6 [16] and
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Mic13/QIL1 [17]. All of these subunits are transmembrane proteins, except for Mic19 and
Mic25.
Mic60 and Mic10 are the core subunits of the two subcomplexes forming the MICOS
architecture (Figure 3). From one side, Mic60 contacts directly with Mic19 and Mic25, while
the remaining subunits assemble with Mic10 [18]. Mic10 interacts with Mic26 and Mic27
and is stabilized by QIL1 [17]. Mic10 has been shown to be able to induce membrane
curvature even in the absence of the other MICOS subunits [19]. Both subcomplexes are
necessary for the formation and stabilization of the cristae at the CJ.
Figure 3. Cartoon of the mitochondrial contact site and cristae organizing system (MICOS) complex at the cristae junction.
Source: adapted from Guarani et al., 2015 [17].
The Mic60/Mic19 module is also associated with the OMM. Indeed, Mic19 has been
shown to form a bridge between Mic60 and Sorting Assembly Machinery 50 kDa subunit
(SAM50), the outer membrane protein that regulates the import and assembly of β-barrel
proteins [20], creating tight OMM and IMM contact sites. Other proteins have been
specifically associated with this OMM–IMM junction such as Metaxin-1 and 2 (Mtx1/Mtx2)
and DnaJ homolog subfamily C member 11 (DNAJC11) [21]. These OMM–IMM interactions
create a specific environment of closed apposition of the two membranes favorable for
protein import and lipid and phospholipid transport [22].
Immunoprecipitation experiments indicate that both Mic19 and Mic60 interact with
OPA1. OPA1 is an IMM protein with a double role in mitochondrial dynamics and archi-
tecture: it is involved in mitochondrial fusion of the IMM and it participates in cristae
remodeling [23,24]. Indeed, OPA1 has been shown to be upstream and epistatic to MIC60
and to be the sole regulator of cristae width and junction diameter and number [25].
Finally, the formation of the cristae rims has been proposed to be also linked to the
dimerization of the ATP synthase. Indeed, Complex V (CV) dimers reside at the apex of the
cristae and, when dimerization is abolished, the IMM loses the typical tubular organization
of the cristae and forms onion-like structures instead, a typical feature associated with
MICOS deregulation [26].
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1.5. Protein Transport through Mitochondrial Membranes
The mechanisms of protein and ion transport through the OMM and the IMM differ
in many aspects [27]. As described previously, the IMM is much less permeable than the
OMM and is characterized by α-helical transport proteins such as protein translocases
and other carriers for metabolites and ions. The OMM, instead, contains channel-forming
proteins, such as β-barrel transmembrane hydrophilic pores, that allow the passage of
precursor proteins, small hydrophilic metabolites and ions.
Human mtDNA only contains 37 genes, while it has been estimated that the mitochon-
drial proteome is composed of approximately 1200 proteins [28]. Consequently, most of the
proteins required are encoded by nuclear genes, translated in the cytosol and transported
to or into the organelle. Indeed, newly synthesized proteins carrying a mitochondrial target
signal are transported to the OMM by chaperones and, according to the nature of their
signal, they can be inserted in the OMM, imported in the IMS or transported to the IMM
translocases [29]. At the OMM, proteins transport is ensured by the two main complexes:
the Translocase of the Outer Membrane (TOM) complex and Sorting and Assembly Ma-
chinery (SAM) complex [30,31]. For insertion of proteins in the OMM, integral proteins
containing one or more spanning helices are not imported, but rather inserted in the OMM
via initial interaction with TOM70 (receptor subunit of TOM) and then, in yeast, with
Mim1, while β-barrel proteins pass through TOM40 (pore subunit of TOM) and are then
transported by chaperones to SAM. The main component of SAM is SAM50, a β-barrel
protein, which interacts with the new protein, accommodates the folding and inserts it
laterally into the membrane [32].
Proteins localized in the IMS can have different fates: they can undergo modifications
to stabilize the protein and prevent retrograde transport, such as insertion of a heme
group or oxidation of cysteine residues in order to form a disulfide bridge via the Mia40
pathway [33]. In addition, modified proteins with a specific target peptide can be directed
to the IMM or the matrix via TIM23 [34].
Proteins that have to be inserted in the IMM are delivered by the IMS chaperones
TIM9-10 to the IMM insertase/translocase complex TIM22, the main pathway for im-
port of polytopic inner membrane proteins [35]. The import through TIM22 requires
the mitochondrial membrane potential, responsible for an electrophoretic effect on the
positively charged targeting sequences of these proteins, but it is not ATP-driven [36].
Finally, Oxa1, a conserved membrane protein, mediates the insertion of both nuclear and
mitochondria-encoded precursors into the inner mitochondrial membrane [37].
For matrix-targeted proteins, the translocase involved in this process is TIM23 and
three different forces drive the transport: the membrane potential, the increasing affinities
of the precursor proteins to the components on the trans side of the translocase, compared
with the affinities to the cis side, and the motor force generated upon ATP hydrolysis by
the chaperone mtHsp70 and its associated subunits [38].
1.6. Mitochondrial Dynamics
Mitochondria are dynamic organelles that form a complex network of tube-like struc-
tures [39]. They undergo opposing fusion and fission events to generate a specific mi-
tochondrial morphology network according to the cellular energy needs, the metabolic
state of the cell or to adapt to cellular cues. Mitochondrial fusion allows the organelles to
share metabolites, proteins and mtDNA, and a hyperfused mitochondrial morphology is
associated with a mechanism of defense to enhance cell survival (and impede mitochon-
drial clearance). In contrast, while mitochondrial fragmentation is often associated with
mitochondrial dysfunction and cell death, this process is also required for mitochondrial
motility or segregation of damaged portions of the reticulum for degradation through a
process known as mitophagy [40].
Mitochondrial dynamics are controlled by Guanosine Triphosphatase (GTPases) pro-
teins belonging to the Dynamin family of proteins, where GTP hydrolysis leads to structural
change, subsequently driving membranes remodeling [41]. During mitochondrial division,
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the constriction of the tubule and membrane scission of one mitochondrion into two sepa-
rate organelles is carried out by recruitment of the cytosolic GTPase Dynamin-related/-like
protein 1 (Drp1) to mitochondria–endoplasmic reticulum (ER) contact sites, via interaction
with fission protein 1 (Fis1) and mitochondrial fission factor (Mff) [39]. At these sites, Drp1
oligomerizes into a ring-like structure and upon GTP hydrolysis drives mitochondrial
division. Mitochondrial fusion, instead, is a two-step mechanism with the OMM localized
GTPases mitofusin 1 and 2 (Mfn1 and Mfn2) ensuring OMM fusion, and the IMM GTPase
OPA1 responsible for IMM fusion. Again, the shape and dynamics of mitochondria are
tightly linked to their bioenergetic status. Failing mitochondria usually appear fragmented,
due to a prevalence of the fission machinery, whereas mitochondria hyperfuse as a mecha-
nism of defense against autophagy in conditions of stress, including bioenergetic stress. In
addition, specific disorders of some main actors of mitochondrial fission (e.g., mutations
in the dynamin-related protein, DRP, the key factor of mitochondrial fission [42,43]) or
fusion (e.g., mitofusin 2, Mfn2 [44], and optic atrophy protein 1, OPA1 [45–47]) can be
associated with OXPHOS failure and, in particular for some OPA1 mutations, with the
accumulation of multiple mtDNA deleted species and multiple defects of the respiratory
chain complex activities [48]. In addition to its profusion role, OPA1 acts also as a sealer of
the cristae junctions and regulates the ordered distribution of the ETC complexes along
the mitochondrial cristae [49,50]. Therefore, alterations in mitodynamics are, nowadays,
considered part of the possible causes of OXPHOS deficiency and bioenergetic failure
leading to mitochondrial disease.
Mitochondria need to move within the cell and their localization is crucial for different
functions such as cell division [51]. Directed mitochondrial transport happens on micro-
tubule filaments, typically through force-generating motor proteins, classified into three
families: myosins, kinesins and dyneins [52]. Milton, syntabulin and the GTPase Miro
have been identified as mitochondria-specific molecules involved in microtubule-based
transport [51].
Mitochondrial trafficking is fundamental for a constant supply of healthy mitochon-
dria generating ATP at the right time and place, especially in neuronal cells, where or-
ganelles have to move over long distances along the axon, from the cell body to the
presynaptic terminal [53].
1.7. Mitochondrial Functions
Mitochondria are commonly known as the “powerhouse of the cell”, due to their role
in energy production. However, in the last 30 years, mitochondria have been characterized
also as a signaling organelle involved in numerous physiological functions, including
calcium homeostasis, apoptosis and heme and iron-sulfur clusters synthesis.
1.7.1. Energy Production
The main source of energy in cells derives from the de-phosphorylation of an ATP
molecule to an adenosine diphosphate (ADP) molecule. In order to make this process
sustainable, the cell needs to use nutrients to re-generate the ATP molecules used.
During a series of chemical reactions, indeed, a glucose molecule is gradually broken
down into carbon dioxide, and its hydrogen atoms are stripped and used to combine
with oxygen to form water. The first stage of this mechanism takes place in the cytosol,
is anaerobic and is mitochondria-independent [54]. This pathway is known as glycolysis,
and it produces only two molecules of ATP from one molecule of glucose metabolized,
generating two molecules of pyruvate.
To optimize ATP production, glycolysis is coupled to a second pathway, known as
the citric acid cycle (or tricarboxylic acid cycle or Krebs cycle, Figure 4), which takes
place in mitochondria and is aerobic. This cycle is composed of nine different enzymatic
reactions and each round generates three nicotinamide adenine dinucleotide (NADH)
molecules, one flavine adenine dinucleotide (FADH2) and one guanosine triphosphate
(GTP). One molecule of glucose is catabolized by glycolysis into two molecules of the
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ketoacid pyruvate. Pyruvate enters through the mitochondrial pyruvate carrier (MPC)
into the mitochondrial matrix [55], where it is decarboxylated, oxidized and coupled with
coenzyme A by pyruvate dehydrogenase, PDH, to form acetyl-CoA. Thus, the two glucose-
derived acetyl-CoA molecules in the mitochondrial matrix lead to a complex catabolic
cycle, the Krebs cycle, which gives rise to two molecules of CO2, whereas their electron
equivalents (hydrogen atoms) are stripped off and used to produce, in total, six NADH,
two FADH2 and two GTP.
Figure 4. Schematic representation of the tricarboxylic acid cycle or Krebs cycle.
NADH and FADH2 molecules can then be used in a process known as oxidative
phosphorylation, where the majority of the energy is finally converted to ATP. This process
consists of the passage of electrons from NADH and FADH2 to the final acceptor, oxygen,
through the electron transport chain (ETC). This process, which involves molecular oxygen
as a sink for binding electrons, is called cellular respiration. Respiration is coupled with
ATP production by ATP synthase or complex V of the ETC. In total, the complete oxidation
of a single molecule of glucose is used by the cell to produce 30 ATP molecules [56].
Importantly, NADH and FADH2 can also be produced by a process known as fatty
acid β-oxidation. A fatty acid is converted to fatty acyl-CoA and then to acyl carnitine, in
order for it to enter the mitochondria and eventually be reconverted in intramitochondrial
acyl-CoA. In the organelle, a long-chain acyl-CoA is broken down to acetyl-CoA molecules,
producing one NADH and one FADH2 for each couple of carbons hydrolyzed from the
acyl chain [57].
The proton gradient produced during respiration, similar to an accumulator, supplies
energy to operate the ATP synthase (complex V) which, through dissipating it, provides
the energy to condense ADP and Pi into ATP. Thus, respiration is distinct but coupled to
phosphorylation, in the oxidative phosphorylation pathway. In a normal adult human
being, this process leads to the daily production of approximately 70 kg of ATP, which
provides the energy necessary for all exergonic reactions of the organism.
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1.7.2. Apoptosis
Mitochondria also play a role in the regulation of programmed cell death, called apop-
tosis, which is required for embryonic development and numerous physiological functions.
Apoptosis leads to a controlled and programmed cell death, which can occur as a response
to various damages or stressors, such as DNA damage, oxidative stress, immune reactions
and absence of certain growth factors, hormones and cytokines, or as a natural part of
development and aging [58]. Different apoptotic pathways exist, characterized by different
triggers but with a common final execution pathway. Indeed, these different pathways
lead to activation of initiator caspases (as caspase 8 and 9), which then activate executioner
caspases (as caspase 3 or 7), to finally induce the degradation of cellular components. The
extrinsic or death receptor pathway, which does not directly involve the mitochondria, is
activated by extracellular ligands binding to death receptors on the plasma membrane and
leads to the formation of the death-inducing signaling complex (DISC), which subsequently
activates the initiator caspase 8 and then the executioner caspase 3 [59]. The best charac-
terized is the mitochondrial or intrinsic pathway of apoptosis. Mitochondrial apoptosis is
initiated by internal signals of stress or damage that usually lead to a bioenergetic failure
and decrease ∆P and it consists in the mitochondrial outer membrane permeabilization
(MOMP), regulated by the Bcl-2 family of proteins. Upon stressors, the pro-apoptotic
members BAX and BAK oligomerize at the OMM [60,61], where they induce the release of
pro-apoptotic proteins from the IMS into the cytosol, including cytochrome c [62]. Once
in the cytosol, cytochrome c binds and activates apoptotic protease activating factor-1
(Apaf-1) as well as procaspase-9, forming a complex known as the “apoptosome”. Active
caspase 9 is then able to cleave and activate caspase 3, starting the communal execution
pathway [63,64]. The execution pathway leads to DNA fragmentation, degradation of
cytoskeletal and nuclear proteins, cross-linking of proteins and formation of apoptotic
bodies. Thus, bioenergetic failure often leads to mitochondrial apoptosis, although it may
also cause autophagy of individual spent mitochondria, or even to ablation of a portion of
dysfunctional portions of mitochondria that are left surviving. Therefore, apoptosis and
related phenomena constitute one of the possible deleterious outcomes of mitochondrial
disease. Importantly, in addition to the release of cytochrome c and formation of the
apoptosome, other mitochondrial proteins can determine apoptosis through alternative
mechanisms, such as the apoptosis inducing factor 1 (AIF1) [65], a redox mitochondrial
membrane-bound protein that in stress conditions can be cleaved by cathepsin or other
proteases, released outside mitochondria and there activate caspases independently from
the formation of apoptosome, eventually leading to apoptosis. Recessive mutations of AIF1
have been reported in severe infantile syndromes associated with multiple defects of the
mitochondrial respiratory chain activities [66].
1.7.3. Calcium Homeostasis
Calcium is largely used in cells as a signaling molecule; therefore, its regulation is crit-
ical. Cellular organelles such as the ER and mitochondria are able to sequester and release
calcium, regulating the cellular concentration of the ions. Vice versa, calcium signaling has
a role in mitochondrial functionality, even if not all the molecular mechanisms involved
are clear yet. What is largely accepted is that calcium in the mitochondrial matrix regulates
various enzymes, such as pyruvate, isocitrate and 2-oxoglutarate dehydrogenases, modu-
lating, as a consequence, mitochondrial respiration, and the induction of the mitochondrial
permeability transition pore [67].
Calcium passes the OMM barrier through a VDAC, which is characterized by high-
conductance and weak anion selectivity [68]. The passage through the IMM, instead, is
more controlled and involves the mitochondrial calcium uniporter (MCU), which transports
Ca2+ inside the matrix, and a Na+/Ca2+ exchanger, mostly expressed in excitable cells,
such as muscles and brain, or an H+/Ca2+ exchanger, in other cell types, which release
calcium from the matrix to the IMS [69].
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1.7.4. Heme Synthesis
Heme is an iron-containing porphyrin, essential in numerous biological processes,
such as oxygen transport and storage, drug and steroid metabolism, signal transduction
and microRNA processing [70]. Moreover, heme is incorporated in some subunits of the
electron transport chain and it is necessary for cellular respiration [71].
The synthesis of this compound occurs both partially in the mitochondria and in
the cytosol [72]. Heme is generated by the insertion of ferrous iron into the tetrapyrrole
macrocycle of protoporphyrin IX [73] catalyzed by a mitochondrial matrix enzyme, called
ferrochelatase. Protoporphyrin IX is produced starting from glycine and succinyl-CoA.
Most of heme production takes place in erythroid progenitors, followed by the liver
for the formation of heme-containing enzymes [73]. The synthesis pathway is conserved in
these two cellular types, while its regulation differs. The heme synthesis machinery in the
liver has a rapid turnover in order to respond quickly to changes in metabolic requirements,
while the synthesis in developing red cells is tied to the availability of iron.
1.7.5. Fe/S Clusters Synthesis
Iron-sulfur (Fe/S) clusters are prosthetic groups with a variety of biological functions.
Indeed, several enzymes, such as glycosylases, helicases, primases and respiratory chain
enzymes, require the incorporation of Fe/S centers for their activity [74]. Both the proteins
containing these centers and the proteins that are part of the biosynthesis machinery are
highly conserved in prokaryotes and eukaryotes, suggesting an important role in the
origin of life [75]. These cofactors originated probably in an environment characterized by
low oxygen and co-evolved when the oxygen levels started increasing in the atmosphere,
leading to the adaptation of anaerobic electron transport chains for an aerobic habitat.
Most Fe/S proteins contain a rhomboid [Fe2/S2], a cuboidal [Fe3/S4] or a cubane [Fe4/S4]
cluster [76]. The most common protein ligand is cysteine, but also histidine, serine and
arginine can form a bond [74].
In yeast, Fe/S clusters synthesis takes place exclusively in mitochondria, but an Fe-
S cluster can also be exported from mitochondria by a specific ABC transporter in the
inner mitochondrial membrane [77]. The central actor of the synthesis pathway found in
eukaryotic mitochondria is known as iron-sulfur cluster assembly enzyme (ISCU), which
acts as a scaffold for the initial synthesis of a [2Fe–2S] cluster. This cluster will be the basis
for the formation of both mitochondrial and cytosolic Fe/S groups. The sulfide ions used
in this process are obtained from cysteine side chains, thanks to the activity of enzymes
called cysteine desulfurases [78], while it is not clear how iron is delivered to the ISCU,
although frataxin may be involved [79].
2. The Electron Transport Chain
The enzymatic machinery performing cellular respiration, the electron transport chain
(ETC), is composed of four protein complexes embedded in the IMM and two mobile
electron carriers (ubiquinone, or coenzyme Q, and cytochrome c) (Figure 5). Electrons are
transported from electron carriers reduced during glycolysis and the Krebs cycle (NADH
and FADH2) to coenzyme Q and cytochrome c and eventually transferred to O2, forming
H2O. The energy liberated by this chain of redox reactions leads to the generation of an
electrochemical proton gradient across the IMM, which is used by complex V or F1Fo ATP
synthase to generate ATP [80,81].
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Figure 5. Cartoon representation of the oxidative phosphorylation (OXPHOS) machinery. NADH
and FADH2 molecules generated during glycolysis and the Krebs cycle are oxidized by complex I
(CI) and complex II (CII), respectively. Electrons are then passed to ubiquinone (Q), which transfers
them to complex III (CIII). Here, they are transferred to cytochrome c (C) and to complex IV (CIV),
where they are used to reduce O2 to H2O. Coupled to electron transfer, protons are pumped from the
matrix (red arrows) to the intermembrane space (IMS) and the proton motive force generated is used
by complex V (CV) to produce ATP.
2.1. Proton Gradient and Proton Motive Force
The formation of the electrochemical gradient is made possible by the nature of the
phospholipidic bilayer that forms the IMM. Indeed, the membrane is impermeable to the
passage of protons, which require protein transporters to cross it. These transporters are
part of complexes I, III and IV and the energy necessary for the proton pumping and the
generation of the electrochemical gradient derives from the transport of electrons.
This gradient produces the proton motive force (PMF or ∆p), which can be described
as a measure of the potential energy stored across the IMM. Since protons are electrically
charged particles, the PMF has both chemical and electric components. The electric com-
ponent corresponds to the voltage difference across the membrane and the free energy is
calculated as ∆G = −F∆Ψ (F = Faraday constant; ∆Ψ = membrane potential). The chemi-
cal component, instead, has a free energy calculated as ∆G = RT ln([H+]i/[H+]o), where
[H+]i and [H+]o refer to the proton concentrations inside and outside the IMM, respec-
tively, R is the gas constant of 1.987 cal/(degree·mol), and T is the temperature (in degrees
Kelvin). Combining these two components, the PMF is calculated as ∆p = ∆Ψ − (RT/F)
* ln([H+]i/[H+]o). Under physiological conditions, the magnitude of the PMF is about
−220 mV [71]. As a consequence of the difference in protons concentration, the matrix side
of the inner mitochondrial membrane is negatively charged and slightly alkaline (pH = 8).
2.2. Electron Transport and Oxidative Phosphorylation
The first actors in the electron transport chain are NADH and FADH2 (Figure 6).
NAD+ and FAD+ are reduced to NADH and FADH2, respectively, during glycolysis or
beta oxidation of fatty acids and the citric acid (Krebs) cycle. A 1:1 mixture of NADH and
NAD+ has a redox potential of −320 mV, while the midpoint redox potential of FADH2 is
around −220 mV. This means that both these molecules have a strong tendency to donate
electrons [54]. The ∆G◦’ values for these strongly exergonic reactions are −52.6 kcal/mol
(NADH) and −43.4 kcal/mol (FADH2) [71].
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Figure 6. Graphic representation of electrons flow through the electron transport chain (ETC) from
NADH, succinate and FADH2 to O2 (dotted arrows). The catalytic centers of the four electron
transport chain complexes are represented. Electrons pass in sequence from carriers with a lower
reduction potential to those with a higher potential. The energy released from the passage of electrons
through the chain is coupled with the pumping of protons across the inner membrane, establishing
the proton motive force (PMF). Adapted from Molecular Cell Biology, 4th edition. W. H. Freeman,
New York.
NADH binds to complex I (CI, NADH dehydrogenase) and is oxidized to NAD+,
donating two electrons to a flavin mononucleotide (FMN) (Figure 6), inserted in CI subunit
NDUFV1. Electrons are then passed to a chain of eight iron-sulfur (Fe/S) clusters, in
order to be eventually transferred to the oxidized form of coenzyme Q or ubiquinone
(Q), which uptakes two protons to form ubiquinol (QH2). As the electrons are transferred
from one redox center to the other, four protons are pumped through CI out of the matrix.
Despite the numerous biochemical and structural studies on CI, a definitive model of redox-
coupled proton pumping does not exist yet. Many models have been proposed: the first
hypotheses suggested conformational changes in antiporter-like subunits in the P-module,
allowed by the energy produced during electron transport [82,83], or transient hydration
changes able to generate water-gated pathways for proton transfer between conserved
ionizable residues along the membrane domain [84]. The energy necessary for the proton
translocation could be provided by two processes: a two-stroke mechanism where the
pumping is coupled with N2 (the terminal cluster in the Fe/S chain) reduction/re-oxidation,
which occurs twice for every NADH oxidized, assuming the transfer of one electron at a
time, or a single-stroke mechanism, where all four protons are translocated together after
the reduction of coenzyme Q [85–87]. More recent analyses of the X-ray structure of the
Y. lipolytica enzyme, instead, led to the hypothesis that proton pumping is linked to the
coordinated conformational rearrangement of three loops in subunits ND1, NDUFS2 and
ND3, triggered by the binding of negatively charged ubiquinone [88].
FADH2 derives from the oxidation of succinate to fumarate by complex II (CII, succi-
nate dehydrogenase) during the Krebs cycle (and the last steps of beta oxidation), a reaction
Int. J. Mol. Sci. 2021, 22, 586 12 of 53
that reduces FAD+ to FADH2, a cofactor bound to the flavoprotein subunit (SDHA). Then,
two electrons are transferred to the Fe/S clusters contained in SDHB, which will eventually
pass them to Q (Figure 6). This process results in an increased ubiquinol pool but does not
directly influence the proton gradient because CII is not a proton pump.
Coenzyme Q is a mobile cofactor that can interact with CI and CII and transports the
electrons received to complex III (CIII, Q-cytochrome c oxidoreductase). CIII oxidizes QH2
to Q and passes the electrons to another soluble carrier, cytochrome c, during a process
known as the Q-cycle (Figure 7). The Q-cycle consists of two parallel reactions, which in-
volve the three prosthetic groups of the enzyme: the heme groups contained in cytochrome
c1 and cytochrome b and the 2Fe/2S cluster contained in the Rieske protein/UQCRFS1 [89].
The first reaction requires the passage of one electron from QH2 bound to the Qo binding
site to the iron/sulfur group and then to cytochrome c1, leading to the reduction of cy-
tochrome c. Each cytochrome c is able to bind only one electron and, when reduced, moves
from CIII to complex IV (CIV, cytochrome c oxidase). The second electron from QH2 is
passed to the two heme b groups (bL and bH) contained in cytochrome b and terminates
on a second ubiquinone molecule bound to a different binding site of the enzyme (Qi
site). This ubiquinone is partially reduced to a semiquinone (Q−•) during the first Q-cycle
and completely reduced to QH2 following a second catalytic cycle [90–93]. One QH2
molecule is then recycled and two electrons are eventually passed to two cytochrome c
molecules. For each QH2 molecule that is oxidized, there is the release of two protons to
the intermembrane space. QH2 has a redox potential around 0 mV, while CIII centers have
a positive potential, allowing the passage of electrons. In order to permit the two branches
of the Q-cycle, different centers of CIII must have different redox potentials, ranging be-
tween 72.5 mV for cytochrome b, low enough to allow the recycling of electrons through
semiquinone, and 242 mV for cytochrome c1, which passes the electron to cytochrome c
(251 mV) [94,95].
Figure 7. Schematic representation of the Q-cycle.
During the Q-cycle, CoQ is present in three different forms, according to its redox
state: ubiquinone (Q), semiquinone (Q−•) and ubiquinol (QH2). According to the phase
of the cycle and the consequent state of the reaction, CoQ molecules can bind CIII in
different binding sites: Qo, which faces the IMS and catalyzes the oxidation of ubiquinol to
ubiquinone, and Qi, which faces the matrix and catalyzes the reduction of ubiquinone to
semiquinone and ubiquinol [96].
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The last steps of oxidative phosphorylation take place in CIV (the terminal oxidase),
which allows the passage of electrons from cytochrome c to oxygen (redox potential =
820 mV), generating water. Since cytochrome c carries only one electron, four molecules
are oxidized in order to generate two H2O molecules from one molecule of O2. In the
meantime, four substrate protons are taken from the matrix to form H2O and the other four
protons are pumped into the IMS [97,98]. CIV contains two heme groups (cytochromes
a and a3) and two copper atoms (CuA and CuB) [99]. Electrons are transferred through
the CuA center and heme a to the heme a3/CuB group. When both heme a3 and CuB
are reduced, one O2 molecule is recruited to form a peroxide bridge between these two
prosthetic groups. This bond is broken by the reaction with protons picked up by the
mitochondrial matrix and two H2O molecules are formed [100].
2.3. Complex I
2.3.1. Structure and Assembly
NADH dehydrogenase (Complex I, CI) is the first step of the electron transport chain
and is composed of 44 different subunits in mammals [101], organized into three structural
domains: a membrane arm, or P-module, and two peripheral domains, the N and the Q
modules, protruding in the mitochondrial matrix. The N module contains the FMN cofactor
and is responsible for the binding and the oxidation of NADH, while the Q module contains
the ubiquinone binding site. The passage of electrons between these two extremities occurs
in Fe/S clusters in both the N and the Q modules. The peripheral arm is composed of
nuclear-encoded proteins, 7 “core” subunits (NDUFV1, NDUFV2, NDUFS1, NDUFS2,
NDUFS3, NDUFS7 and NDUFS8) and 30 accessory subunits necessary to stabilize the
enzyme and to protect it from reactive oxygen species (ROS) damage [102]. The P-module,
instead, is deputed to the proton pumping activity and contains seven mtDNA-encoded
proteins: ND1, ND2, ND3, ND4, ND4L, ND5 and ND6. ND1 forms the reduction site for
ubiquinone, while ND2, ND4 and ND5 have been found to share a similar structure to
sodium and potassium antiporters and may be involved in proton pumping [103]. The
mammalian CI structure is represented in Figure 8.
Figure 8. Representation of CI structure. Image has been created with BioRender.com using the
structural data retrieved from PDB (5LC5).
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Due to the large number of subunits forming CI, the assembly pathway of this enzyme
is particularly complex and requires the involvement of many assembly factors. The
first stage is the synthesis of the various subunits, both inside mitochondria and in the
cytoplasm, coupled with the import in the organelle of the nuclear-encoded components.
Most CI subunits have N-terminal mitochondrial targeting sequences (MTS), while 11 are
imported into the organelle thanks to uncharacterized internal signals within the mature
protein [104]. Several core subunits need further maturation and the insertion of the
prosthetic groups. However, it is difficult to identify assembly factors with this role using
traditional proteomic analysis, probably because of the transient and labile interaction
between them and the forming enzyme [105]. The only assembly factor known to be
involved in the incorporation of 4Fe/4S clusters in the peripheral arm is NUBPL, a member
of the Mrp/NBP35 ATP-binding protein family [106,107]. Moreover, it is not clear if the
insertion of the iron/sulfur clusters happens before or after the incorporation of the single
subunit into the subcomplex.
The second step of CI assembly is the formation of six independent modules, N, Q,
ND1/PP-a, ND2/PP-b, ND4/PD and ND5/PD-b, and the incorporation of each of them in
a specific order [108]. All the known CI assembly factors are summarized in Table 1.
The ND2 module is the first detectable after inhibition of mitochondrial protein
biosynthesis [109]. This subassembly binds to numerous assembly factors: ACAD9, ECSIT,
TMEM126B, NDUFAF1, COA1 and the putative assembly factor TMEM186, which form
the mitochondrial complex I intermediate assembly (MCIA) [110]. Moreover, TMEM186
was found to strongly interact with the newly synthesized MT-ND3, which is added to the
intermediate together with MT-ND6 and MT-ND4L, forming a 385 kDa structure.
In parallel to this, an intermediate of the Q module starts forming, binding to ND-
UFAF3 and NDUFAF4 and generating a ~170 kDa structure. This submodule will then
bind to the assembly factor TIMMDC1 and the subunits ND1, NDUFA3, NDUFA8 and
NDUFA13, to yield a 283 kDa complex [109].
The ND4 module, instead, involves the subunits NDUFB1, NDUFB4, NDUFB5,
NDUFB6, NDUFB10 and NDUFB11, together with the assembly factors FOXRED1, ATP5SL
and TMEM70. This 230 kDa module binds initially to the N2 module and then to the
ND1/Q module intermediate [109].
The ND5 module, which forms the distal extremity of the membrane arm, is the
second to last intermediate inserted into the forming enzyme. It is composed of the
subunits NDUFB2, NDUFB3, NDUFB7, NDUFB8, NDUFB9 and NDUFAB1, and it is
known to bind one assembly factor: DMAC1/TMEM261 [111]. This late intermediate
lacking the N module is stabilized by NDUFAF2/NDUFA12L/B17.2L.
Finally, the N module, composed of NDUFV1, NDUFV2, NDUFS1 and NDUFA2,
forming a 160 kDa assembly, is incorporated [109]. This last passage completes the assembly
of the enzyme, which loses the interaction with the assembly factors and stabilizes as a
~1000 kDa complex.
Table 1. CI assembly factors. Adapted from Giachin, 2016 [112], and Sanchez-Caballero et al., 2016 [105].
Assembly Factor Function CI Interacting Module References
ACAD9 Binding of ND2 module ND2/PP-b module [113,114]
ECSIT Insertion of ND2 ND2/PP-b module [115]
FOXRED1 In a complex with AIFM1 and ACAD9 ND4/PD module [116,117]
ATP5SL Binding of ND4 module ND4/PD module [118]
TMEM70 Binding of ND4 module ND4/PD module [119,120]
NDUFAF1 Insertion of ND2 module N module, ND1 [121]
NDUFAF2 Binding of N module N module [122]
NDUFAF3 Binding of Q with PP-a Q module [123]
NDUFAF4 Binding of Q with PP-a Q module [124]
NDUFAF5 Methyltransferase activity Not known [125,126]
NDUFAF6 Squalene/phytoene synthase activity Not known [127]
NDUFAF7 Methyltransferase activity Not known [128,129]
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Table 1. Cont.
Assembly Factor Function CI Interacting Module References
NUBPL 4Fe/4S clusters insertion. Necessary for theentire enzyme stability
Supposed to interact with the developing
N module and possibly Q module [106,107,130]
TIMMDC1 Translocase of inner mitochondrialmembrane domain-containing protein 1 ND1/PP-a [118,131]
TMEM126B Required for formation of the ND2 module ND2/PP-b module [132]
TMEM186 Not known ND2/PP-b module [109]
DMAC1/TMEM261 Stabilization and/or assembly of ND5 ND5/PD-b [111]
COA1 CIV assembly factor, found bound to CIassembly intermediates ND2/PP-b module [109]
2.3.2. Pathologies Associated with Complex I Deficiency
Mutations affecting CI stability or activity are responsible for a wide range of patholog-
ical phenotypes [133]. Missense mutations affecting the mitochondrial-encoded subunits
(ND subunits) have been associated with Leber’s hereditary optic neuropathy (LHON),
mitochondrial encephalomyopathy, lactic acidosis and stroke-like syndrome (MELAS) and
Leigh syndrome. Many mutations in nuclear-encoded subunits have been identified in pa-
tients with CI deficiency, causing Leigh syndrome, leukoencephalopathy, leukodystrophy,
encephalopathy, cardiomyopathy and other neurological defects. In addition, assembly
factors and chaperones involved in CI assembly can also be at the origin of the pathogenesis
of these diseases [134]. The main pathological mutations found in CI subunits or assembly
factors are summarized in Table 2.
Table 2. CI subunits and assembly factors associated with mitochondrial diseases.
Gene/Protein OMIM Associated Phenotype Reference
Complex I subunits
MTND1 516000 Leber optic atrophy, MELAS syndrome, dystonia, spasticity and myopathy. [135–137]
MTND2 516001 Leber optic atrophy. [138]
MTND3 516002 Infantile encephalopathy and Leigh syndrome. [139]
MTND4 516003 Leber optic atrophy and MELAS syndrome. [140,141]
MTND4L 516004 Leber optic atrophy. [142]
MTND5 516005 Leber optic atrophy and MELAS syndrome. [143,144]
MTND6 516006 Leber optic atrophy and MELAS syndrome. [143,145]
NDUFV1 161015 Severe encephalopathy and neurologic abnormalities. [146,147]
NDUFV2 600532 Hypertrophic cardiomyopathy, truncal hypotonia and encephalopathy. [148]
NDUFS1 157655 Growth retardation, axial hypotonia, hepatomegaly, dystonia and persistenthyperlactatemia. [147]
NDUFS2 602985 Neonatal lactic acidosis and hypertrophic cardiomyopathy. [149]
NDUFS3 603846 Leigh syndrome, severe axial dystonia with oral and pharyngeal motor dysfunction,dysphagia and a tetraparetic syndrome. [150]
NDUFS4 602694 Muscular hypotonia, absence of visual and auditive attention and cardiac defects. [151]
NDUFS6 603848 Fatal infantile lactic acidosis. [152]
NDUFS7 601825 Leigh syndrome, feeding problems, dysarthria and ataxia. [153]
NDUFS8 602141 Leigh syndrome, poor feeding and episodes of apnea and cyanosis. [154]
NDUFA11 612638 Fatal infantile metabolic acidosis, brain atrophy, no motor development andhypertrophic cardiomyopathy. [155]
NDUFA1 300078 Leigh syndrome, hypotonia, nystagmus, generalized choreoathetosis and decreasedreflexes. [156]
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Table 2. Cont.
Gene/Protein OMIM Associated Phenotype Reference
NDUFA2 602137 Leigh syndrome, hypertrophic cardiomyopathy and developmental delay. [157]
NDUFA6 602138 Intrauterine growth retardation, respiratory insufficiency, lactic acidosis andhypoglycemia. [158]
NDUFA8 603359 Severe neonatal hypotonia, dysmorphic features, epilepsy and signs of brainsteminvolvement. [159]
NDUFA9 603834 Respiratory and metabolic acidosis, hearing loss, apneas and retinitis pigmentosa. [160]
NDUFA10 603835 Leigh syndrome and delayed psychomotor development. [161]
NDUFA12 614530 Leigh syndrome, progressive loss of motor abilities, scoliosis and dystonia. [162]
NDUFA13 609435 Delayed development, hypotonia, poor eye contact, abnormal eye movements, poorfeeding, encephalopathy and hearing loss. [163]
NDUFB3 603839 Encephalopathy, myopathy, hypotonia, developmental delay and lactic acidosis. [164]
NDUFB8 602140 Leigh syndrome, respiratory failure, seizures, hypotonia, cardiac hypertrophy, failureto thrive and severely delayed psychomotor development. [165]
NDUFB9 601445 Progressive hypotonia associated with increased serum lactate. [164]
NDUFB10 603843 Lethal complex I deficiency. [166]
NDUFB11 300403 X-linked microphthalmia with linear skin defects (MLS) syndrome, cardiomyopathyand other congenital anomalies. [167,168]
NDUFC2 603845 Leigh syndrome. [169]
Complex I assembly factors
ACAD9 611103 Cardiorespiratory depression, hypertrophic cardiomyopathy, encephalopathy andsevere lactic acidosis. [114]
FOXRED1 613622 Leigh syndrome, congenital lactic acidosis, athetoid movements of the limbs in earlychildhood, hypotonia and cerebellar atrophy. [170]
NDUFAF1 606934 Hypertrophic cardiomyopathy, developmental delay, lactic acidosis, hypotonia andWolff–Parkinson–White syndrome. [171]
NDUFAF2 609653 Ataxia, lethargy, nystagmus, hypotonia, optic atrophy and episodic respiratoryinsufficiency. [122]
NDUFAF3 612911 Macrocephaly, weak cry, no eye contact, wide anterior fontanel and axial hypotonia. [123]
NDUFAF4 611776 Severe encephalopathy and antenatal cardiomyopathy. [124]
NDUFAF5 612360 Facial dysmorphism, progressive lactic acidosis and neurological defects. [125]
NDUFAF6 612392 Focal seizures, decreased movement and strength, ataxia, lactic acidosis and Leighsyndrome. [172]
NDUFAF8 618461 Leigh syndrome. [173]
NUBPL 613621 Infantile-onset hepatopathy, renal tubular acidosis, developmental delay, short stature,leukoencephalopathy, myopathy, nystagmus and ataxia. [106,107,130]
TIMMDC1 615534
Infantile-onset hypotonia, failure to thrive, delayed or minimal psychomotor
development, sensorineural deafness, dysmetria, dyskinetic movements, peripheral
neuropathy, nystagmus and Leigh syndrome.
[174]
TMEM126B 615533 Exercise intolerance, muscle weakness, myalgia, early-onset renal tubular acidosis andhypertrophic cardiomyopathy. [175,176]
COA7 615623 Autosomal recessive spinocerebellar ataxia with axonal neuropathy-3. [177]
2.4. Complex II
2.4.1. Structure and Assembly
Succinate dehydrogenase (SDH, complex II, CII) is a ~120 kDa integral membrane
complex, involved in both the TCA cycle and the ETC. Indeed, this enzyme catalyzes the
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oxidation of succinate to fumarate, a central step of the citric acid cycle, and reduces FAD
to FADH2, which then reduces ubiquinone to ubiquinol [178]. CII is the only complex of
the chain that does not pump protons across the membrane and that is entirely encoded by
the nuclear DNA.
CII is composed of four subunits, named SDHA-D, forming two domains (Figure 9).
The hydrophilic head of CII comprises SDHA and SDHB and is required for the oxidation
of succinate. FAD+ binds to SDHA and the electrons are transferred to SDHB, containing
three Fe/S clusters ([2Fe-2S], [4Fe-4S] and [3Fe-4S]) [179]. The hydrophobic membrane
domain of the enzyme is composed of SDHC and SDHD and contains a heme b group and
two ubiquinone binding sites [180].
Figure 9. Representation of E. coli CII structure. The four subunits forming the complex (SDHA-D)
are shown in different colors and labeled with the letters A to D. FAD, Fe-S centers, heme b and the
ubiquinone binding site facing the matrix (Qp) are indicated. Source: Iverson, 2013 [181].
The mature forms of SDHA and SDHB are generated independently before the com-
plex assembly, while SDHC and SDHD are able to form an intermediate subcomplex [182].
SDHA is initially imported into the matrix as an apo-protein and the FAD cofactor is in-
serted thanks to the interaction with the assembly factor SDHAF2/Sdh5 [183]. Then, mature
SDHA binds to SDHAF4/Sdh8, a chaperone that protects the subunit from auto-oxidation
and facilitates the assembly with SDHB. Mature SDHB contains Fe/S clusters, which are
inserted by SDHAF1 [184,185]. SDHB stability is then maintained by the association with
an LYR motif protein recently identified in yeast, Sdh7 (SDHAF3/ACN9/LYRM10, human
ortholog), which shields one or more of the prosthetic centers from oxidants [186]. Mature
SDHA and SDHB are then able to assemble together and join SDHC and SDHD and insert
into the membrane via a still uncharacterized mechanism.
2.4.2. Pathologies Associated with Complex II Deficiency
Patients presenting with a specific CII defect are quite rare, less than 10% of OX-
PHOS deficiency cases [187]. Two main phenotypes can originate from mutations in CII
subunits or assembly factors. Mutations in SDHAF1 and SDHA lead to encephalomyopa-
thy and leukoencephalopathy [184,188], while variants in SDHA, SDHB, SDHC, SDHD
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and SDHAF2 are responsible for hereditary paraganglioma and pheochromocytomas,
rare neuroendocrine tumors [183,189–192]. Moreover, other genes involved in FAD and
Fe/S cluster synthesis can impair CII activity and stability [193]. The main pathological
mutations found in CII subunits or assembly factors are summarized in Table 3.
Table 3. CII subunits and assembly factors associated with mitochondrial diseases.
Gene/Protein OMIM Associated Phenotype Reference
SDHA 600857 Leigh syndrome, neonatal dilated cardiomyopathy,catecholamine-secreting extra-adrenal paraganglioma. [194–196]
SDHB 185470 Paraganglioma, pheochromocytoma, gastrointestinal stromal tumors. [197,198]
SDHC 602413 Paraganglioma, gastric stromal sarcoma. [190,199]
SDHD 602690 Paraganglioma, pheochromocytoma, gastric stromal sarcoma. [191,199]
SDHAF1 612848 Leukoencephalopathy, spastic quadriplegia, psychomotor regression. [184]
SDHAF2 613019 Paraganglioma. [183]
2.5. Complex III
2.5.1. Structure and Subunits
The ubiquinol:cytochrome c oxidoreductase (cytochrome bc1, complex III, CIII) is the
central element of the respiratory chain. In yeast, it is formed of 10 different subunits, while
in mammals, an additional subunit was identified, corresponding to the mitochondrial tar-
geting sequence of the Rieske protein/UQCRFS1, which remains anchored to the complex
after the proteolytic cleavage [200]. However, recent studies proposed that the latter is not
a stoichiometric subunit and that the N-terminal UQCRFS1 peptide needs to be eliminated
in order to maintain the functionality of CIII [201,202]. All CIII subunits are encoded by
nuclear DNA except cytochrome b (MTCYB), which is mitochondrial-encoded [92,203].
CIII is always dimeric and high-resolution crystal structures of the bovine, chicken and
yeast bc1 complexes have been resolved [91,204–206] (Figure 10).
Figure 10. Representation of bovine CIII structure. CIII is shown as a dimer, the only form in which
it is found in cells. All the 10 subunits are represented with a different color in one monomer. Source:
Sousa et al., 2018 [207].
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Both in yeast and mammals, CIII contains three protein subunits with redox prosthetic
groups: cytochrome b, which contains both the high-potential bH (b562) and the lower-
potential bL (b565) heme centers, cytochrome c1 (CYC1), containing the c-type heme c1, and
the Rieske iron-sulfur protein (Rip1 in yeast, UQCRFS1 protein in mammals) with a 2Fe–2S
cluster [208]. The di-heme cytochrome b polypeptide forms eight transmembrane helices
and contains two histidine residues in each of the second (helix B) and fourth (helix D),
forming the binding site for quinone [209]. The low-potential heme bL is located on the
intermembrane space side of the IMM, while the high-potential heme bH is positioned in
a cavity accessible from the matrix, where it can receive electrons from bL and pass them
to the Qi site, where it reduces one bound ubiquinone to semiquinone [208]. CYC1 has a
wedge-like structure containing the heme group and is anchored in the membrane through
a C-terminal transmembrane anchor next to helix E of cytochrome b [93]. The heme group
binds a CXXCH domain, highly conserved in c-type cytochromes. UQCRFS1 contacts
MTCYB on one of the two CIII heterodecamers with its N-terminal transmembrane domain,
where it receives one electron and undergoes a conformational change that makes it reach
CYC1 on the other one [210]. The maturation of UQCRFS1 has been studied in detail in
simpler organisms, such as Neurospora crassa and Saccharomyces cerevisiae [211]. The newly
synthesized protein undergoes two post-translational modifications: the cleavage of a
targeting pre-sequence and the insertion of the iron-sulfur cluster into the mitochondrial
matrix. Initially, the MTS is cleaved by a mitochondrial matrix protease (MPP), and finally,
an extra eight-amino acid-long sequence is removed by a mitochondrial intermediate
protease (MIP). Contrary to yeast and birds, mammalian UQCRFS1 maturation generates
a 78-amino acid-long fragment, which remains temporally bound to CIII as an eleventh
subunit, Subunit 9 (Su9) [200]. This additional subunit localizes between the two core
subunits UQCRC1 and UQCRC2 and it has been proposed that these two are responsible
for the cleavage of UQCRFS1, due to the conservation of their MPP function [212–214].
The remaining subunits are accessory and their function is mainly to support and
stabilize the complex [215,216].
2.5.2. Assembly
The CIII assembly pathway has been studied in depth in S. cerevisiae [217–221], while
the human CIII assembly model has been initially constructed by homology, as some of the
steps have been shown to be analogous to yeast [222], and recently updated following our
study on CIII-deficient cybrids [223].
The first step of CIII assembly, both in yeast and in mammals, is the synthesis and the
insertion into the IMM of cytochrome b. Yeast cytochrome b contains introns and requires
processing [224], while mammalian MTCYB is transcribed as a polycistronic segment.
MtDNA is organized so that mRNAs coding for proteins are divided by tRNAs, which
assume a specific secondary structure, and function as punctuation marks between the
genes. tRNAs are then cleaved by mitochondrial RNase P at the 5′ ends and by RNase Z at
the 3′ ends, and mRNAs are then translated [225]. Moreover, studies in mice suggested
the involvement of PTCD2 (pentatricopeptide repeat domain protein 2) in processing the
pre-processed ND5-CYTB RNA transcript [226].
The transcription and translation of cytochrome b must be coordinated with the
synthesis of nuclear-encoded proteins. This mitochondrial–nuclear communication is
possible thanks to a group of proteins called translational activators. These nuclear-encoded
factors regulate the expression of mitochondrial genes and their own expression in relation
to the OXPHOS activity, in order to limit the accumulation of unused subunits, which can
have toxic effects on the organelle. In yeast, four translational activators of COB have been
identified: Cbp1, Cbs1, Cbs2 and the complex Cbp3/Cbp6 [220]. These factors interact with
mitochondrial ribosomes and the mitochondrial organization of gene expression (MIOREX)
complex [227]. The primary role of Cbp1 is to protect COB mRNAs and to transfer them
to the translational apparatus [228]. Cbs1 and Cbs2 have been found associated in the
same high-molecular weight complex with mitochondrial ribosomes, but they might also
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form other subcomplexes including those with different activator proteins, such as COX-
specific activators [229,230]. Recent studies on Cbs1 determined that this protein binds to a
segment of the 5′ UTR of COB mRNA, sequestering it and repressing the translation. Cbs1
is then replaced by the complex Cbp3/Cbp6 liberated during assembly, which activates
the translation [231]. These proteins, necessary for the stability of COB mRNA and its
translation, do not have orthologs in mammals [220].
The Cbp3-Cbp6 complex, instead, plays a role in the second phase of translation,
binding the nascent polypeptide exiting the ribosome, and it does not leave the protein
until the incorporation of the bL heme group [232,233]. This complex has orthologs in
mammals named ubiquinol-cytochrome c reductase complex assembly factors 1 and 2
(UQCC1 and UQCC2), with the same function [234]. Cbp3 interacts directly with Cbp4
(human ortholog: UQCC3), an assembly factor anchored in the IMM and protruding into
the intermembrane space. Cbp4 is not necessary for complete translation and release from
ribosomes of cytochrome b, but it has a role in the stabilization of the semihemylated
intermediate that contains bL [232,233]. Together, Cbp3–Cbp6, Cbp4 and cytochrome b
compose intermediate I. In yeast, the now mature cytochrome b forms a subcomplex with
the subunits Qcr7 and Qcr8, called intermediate II. Deletion of any of the genes encoding
cytochrome b, Qcr7 or Qcr8 leads to the almost complete loss of the other two subunits and
Qcr6, while the other subunits are only partially reduced [235]. Similarly, the mammalian
orthologs UQCRB and UQCRQ are incorporated in the early stages of CIII assembly,
provoking the release of the UQCC1-UQCC2 complex.
The following steps of CIII assembly, instead, have been proposed to differ between
yeasts and mammals. The order of incorporation in S. cerevisiae was determined by gen-
erating yeast mutants for single CIII subunits and studying the stability of the remaining
components of the complex [217–219]. The third intermediate step involves the insertion
of four subunits: Qcr6 (UQCRH in humans), the two large structural core subunits Cor1
and Cor2 (UQCRC1 and UQCRC2), and cytochrome c1 (Cyt1). At this stage, dimerization
occurs by joining assembly intermediate II and the Cor1/2 modules [236]. Interestingly,
Cor1, Cor2 and cytochrome c1 were found associated in a subassembly module, even if
the contacts between the core proteins and the catalytic subunits in the fully assembled
enzyme are minimal [217]. Surprisingly, the complex Cor1/Cor2 was detected in various
subcomplexes in two-dimensional electrophoresis. This behavior might be due to the
association of these subunits with other proteins or ETC complexes in the IMM or to the
formation of Cor1/Cor2 aggregates. However, these subassemblies were detectable only
in mutant strains and disappeared when the complex was assembled correctly; therefore,
they might not represent a physiological intermediate. The last assembly factor that might
have a role in the early or intermediate phases of CIII assembly is Bca1, an inner membrane
protein found only in fungi [237]. However, its function is not clear yet.
Taking advantage of CIII-deficient transmitochondrial cybrids carrying a mutation
in MTCYB, however, we recently highlighted two important differences between these
steps of CIII biogenesis in yeasts and in humans [223]. Firstly, we observed the formation
of subassemblies containing CYC1, UQCR10 and potentially UQCRH, while our data
did not suggest any interaction of CYC1 with the core subunits UQCRC1 and UQCRC2.
Secondly, we identified CIV subunits, mainly belonging to the MTCO2 module, consistently
interacting with this intermediate in the CIII-mutant cells. These results suggest that
CIII might use CIV or CIV modules as a structural scaffold in a physiological context, or
sequester CIV-specific subunits or intermediates when supercomplex formation is impaired,
as a control mechanism to inhibit the complete biogenesis of the enzyme. The yeasts-based
and the updated CIII assembly models are shown in Figure 11.
A requirement for the generation of intermediate III is the synthesis, the import and
the maturation of Cyt1. Cyt1 contains a single heme center and is anchored to the IMM via
a single transmembrane segment near its C-terminus [91]. The precursor of this subunit
is translated in the cytosol and transported through TOM and TIM complexes into the
mitochondria. The cytochrome c1 precursor protein contains an N-terminal cleavable
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bipartite pre-sequence [238]. The first of the two independent sequences, a strongly basic
region of 35 amino acids, is a mitochondrial targeting signal and it is proteolytically
removed by MPP in the matrix. The second sequence is a hydrophobic sorting sequence,
which targets Cyt1 to the IMM. However, two models have been proposed to explain this
process. The first one proposes that the whole protein, and therefore both the targeting
sequences, reach the mitochondrial matrix and that only later is the second sequence re-
located into the membrane, allowing the proteolytic cleavages [239]. Instead, in the second
model, only the first segment reaches the mitochondrial matrix, while the second internal
hydrophobic sequence remains anchored in the membrane, stopping the import. In the
matrix, the positive-charged mitochondrial targeting sequence is cleaved by MPP. At the
same time, the C-terminal alpha-helix gets inserted into the membrane and the heme center
is attached to the protein. The hemylation is mediated by holocytochrome c1 synthetase
(Cyt2 or HCCS1 in mammals) [240]. This modification provokes a conformational change
that allows the exposure and the cleavage of the second targeting sequence by Imp2
(inner membrane peptidase 2), leaving the N-terminus of the mature Cyt1 soluble in the
intermembrane space [241].
The late assembly stages involve the incorporation of Qcr9 (mammalian UQCR10) in
yeasts, and Qcr10 (UQCR11) and Rip1 (UQCRFS1) both in yeasts and mammals. Firstly,
Qcr9 is inserted [242]. This small (7.3 kDa) accessory subunit is necessary for the function-
ality of the complex and its deletion results in the formation of a nearly inactive enzyme.
Indeed, it has been observed that, lacking Qcr9, the conformation of Rip1 is altered and
the Fe/S cluster is not incorporated correctly [243]. The last two proteins to be inserted are
Qcr10 and Rip1. Qcr10 is an 8.5 kDa supernumerary subunit incorporated before Rip1 and
required for its stabilization. However, it is not clear yet how and when it is recruited [244].
Many studies, instead, have been published about the maturation and insertion of the
Rieske protein both in yeast and mammals.
Prior to the insertion, Rip1 is imported into mitochondria and receives its 2Fe/2S
center, likely by the resident iron-sulfur cluster (ISC) system. In yeast, the import is
followed by two proteolytic steps that eliminate the N-terminal MTS. The precursor form
is first processed by a matrix MPP protease into an intermediate form [245]. The second
cleavage generates the mature form of the protein and is catalyzed by the mitochondrial
intermediate peptidase (MIP). At this point, Rip1 is transported back across the IMM into
the intermembrane space, where it is assembled in the complex. In mammals, however, the
UQCRFS1 N-terminal import signal is cleaved in a single step when the protein is already
incorporated in the complex and the cleaved segment remains attached to the enzyme [200].
Two assembly factors are necessary for the Rieske protein assembly in both mammals
and yeast: Bcs1 (BCS1L in mammals) and Mzm1 (LYRM7). Bcs1 is a 456 amino acid pro-
tein formed by three different domains: a positively charged 126 amino acid N-terminal
targeting signal [246], a central Bcs1p-specific domain and a highly conserved C-terminal
AAA-ATPase domain [247]. It has been initially proposed that Bcs1p might have a role
in Fe/S cluster insertion, act as a chaperone [248] or bind to the partially formed CIII
in an ATP-dependent manner, keeping it in a state that allows the incorporation of the
Rieske protein [249]. The most recent theory is that Bcs1 is responsible for the export of
the Rieske Fe/S domain from the matrix into the intermembrane space [250]. Bcs1, indeed,
is able to recognize the correctly folded Rieske protein and act as a protein translocase.
This model has been confirmed by the determination of the cryogenic electron microscopy
(cryo-EM) structure of Bcs1 in yeast [251] and mice [252], which suggested an airlock-like
mechanism for Rip1/UQCRFS1 translocation. Bcs1, indeed, seems to form two large aque-
ous vestibules, a bigger one on the matrix side and a smaller one in the inner membrane,
through which the Rieske protein is transported.
Mzm1 is a 14 kDa protein located in the mitochondrial matrix. It was initially thought
to be involved in the modulation of the zinc pool and to this function it owes its name
(mitochondrial zinc maintenance 1) [253]. However, in addition to the reduced zinc pool,
cells lacking Mzm1 have a defect in CIII due to faulty insertion of Rip1 [254]. Its role is
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to stabilize Rip1 in the matrix before the translocation to the IMM. The same function is
shared by the human ortholog, LYRM7 or MZM1L [255].
Finally, the third factor necessary for UQCRFS1 metabolism, which does not have a
yeast ortholog, is TTC19 [256]. TTC19 binds to CIII after the incorporation of UQCRFS1
and is involved in the clearance of UQCRFS1 fragments, a process that is necessary to keep
the complex in a functionally competent state [201]. A complete list of CIII subunits is
indicated in Table 4 and the latest model of the CIII biogenesis pathway is represented in
Figure 11.
Figure 11. Schematic representation of human CIII assembly model based on the homology with the available data for S.
cerevisiae [217–219,221,232,233,236,250,254,257], and of our updated model [220].
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Table 4. List of CIII subunits and factors involved in CIII assembly, both in S. cerevisiae and humans.
S. cerevisiae Homo sapiens
Gene Protein Gene Protein Reference(ID Yeast)
Complex III subunits
COR1 Cor1 UQCRC1 UQCRC1 [258]
COR2 Cor2 UQCRC2 UQCRC2 [259]
COB Cytb MT-CYB Cytochrome b [260]
CYT1 Cytc1 CYC1 CYC1 [238]
RIP1 Rip1 UQCRFS1 UQCRFS1 [261]
QCR6 Qcr6 UQCRH UQCRH [262]
QCR7 Qcr7 UQCRB UQCRB [263]
QCR8 Qcr8 UQCRQ UQCRQ [264]
QCR9 Qcr9 UQCR10 UQCR10 [242]
QCR10 Qcr10 UQCR11 UQCR11 [244]
- - UQCRFS1 UQCRFS1 -
Translation factors Function Reference
CBP1 Cbp1 - - Translational activator of COB mRNA [265]
CBS1 Cbs1 - - Translational activator of COB mRNA [266]
CBS2 Cbs2 - - Translational activator of COB mRNA [266]
CBP3 Cbp3 UQCC1 UQCC1 Translational activator of COB [267]
CBP6 Cbp6 UQCC2 UQCC2 Translational activator of COB [268]
Assembly factors
CBP3 Cbp3 UQCC1 UQCC1 Cytochrome b assembly factor [267]
CBP6 Cbp6 UQCC2 UQCC2 Cytochrome b assembly factor [268]
CBP4 Cbp4 UQCC3 UQCC3 Cytochrome b assembly factor [269,270]
FMP25 Bca1 - - Early/intermediate stages assemblyfactor in fungi [237]
CYT2 Cyt2 VPS53 HCCS1 Heme lyase (Cytochrome c1) [240]
CYC2 Cyc2 - - Cytochrome c1 and cytochrome cassembly factor [271]
BCS1 Bcs1 BCS1L BCS1L AAA-ATPase involved in Rieskeprotein incorporation
[248–
250,272]
MZM1 Mzm1 LYRM7 LYRM7 Matrix protein involved in Rieskeprotein incorporation [253,255,257]
- - TTC19 TTC19 Rieske protein metabolism [256]
2.5.3. Pathologies Associated with Complex III Deficiency
Pathologies due to deficiencies in CIII activity are relatively infrequent and most of
them derive from mutations in MTCYB, the only mtDNA-encoded subunit. Mutations
in this protein are generally associated with myopathy and exercise intolerance [193].
Defects in nuclear-encoded subunits are rarer, but a handful of mutations have been
found in several patients (Table 5). The majority of the pathological variants associated
with mitochondrial CIII deficiency of nuclear origin are found in BCS1L [273]. The genes
found mutated in patients with CIII deficiency and the relative clinical phenotypes are
summarized in Table 5.
Table 5. CIII subunits and assembly factors associated with mitochondrial diseases.
Gene/Protein OMIM Associated Phenotype Reference
Complex III subunits
UQCRC2 191329 Hypoglycemia, lactic acidosis, ketosis and hyperammonemia. [274]
MTCYB 516020 Leber optic atrophy, exercise intolerance, encephalomyopathy, cardiomyopathy andmultisystemic disorder. [275–279]
CYC1 123980 Neurologic deterioration, insulin-responsive hyperglycemia, ketoacidosis with increased serumlactate, liver failure and hyperammonemia. [280]
UQCRB 191330 Gastroenteritis, liver enlargement, hypoglycemia and metabolic acidosis but normalpsychomotor development at age 4. [216]
UQCRQ 612080 Severe neurologic phenotype. [215]
UQCRFS1 191327 Cardiomyopathy and alopecia totalis. [281]
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Table 5. Cont.
Gene/Protein OMIM Associated Phenotype Reference
Complex III assembly factors
BCS1L 603647 GRACILE Syndrome, Bjornstad Syndrome, myopathy, encephalopathy, proximal tubulopathyand liver failure. [272,273,282–288]
TTC19 613814 Progressive encephalopathy, ataxia, spastic paraparesis and psychiatric phenotype. [256,289–292]
LYRM7 615831 Neurological decompensation and regression, leukoencephalopathy and liver failure. [293,294]
UQCC2 614461 Intrauterine growth retardation, neonatal lactic acidosis and renal tubular dysfunction. [234,295]
UQCC3 616097 Lactic acidosis, hypoglycemia, hypotonia and delayed development. [270]
2.6. Complex IV
2.6.1. Structure and Subunits
Cytochrome c oxidase (COX, complex IV, CIV) is the terminal step of the ETC. The
enzyme has a molecular mass of about 200 kDa and in mammals it is composed of 13 sub-
units, 10 nuclear-encoded and 3 encoded by the mtDNA (MTCO1, MTCO2 and MTCO3),
which form the functional core of the complex [296] (Figure 12). However, recently a 14th
subunit, NDUFA4, previously attributed to CI, has been described [297,298] and was found
to be incorporated in the structure of monomeric human CIV [299].
MTCO1 contains three prosthetic groups: cytochrome a3 and CuB, which form the
bi-nuclear center that binds oxygen, and cytochrome a. MTCO2 incorporates the CuA cen-
ter [300] and MTCO3 does not have catalytic activity. The remaining subunits (COX4, 5A,
5B, 6A, 6B, 6C, 7A, 7B, 7C, 8A) are thought to have a structural role in the stabilization of the
complex. Interestingly, CIV is the only ETC complex that evolved tissue-, developmental-
and species-specific isoforms for COX subunits 4, 6A, 6B, 7A, 7B and 8A [301], probably in
order to regulate ATP and energy production in different conditions [302].
Figure 12. Representation of bovine CIV dimeric structure, obtained from X-ray crystallography
(SFX). The functional core of the complex is composed of the mitochondrial-encoded subunits MTCO1
(green), MTCO2 (dark blue) and MTCO3 (yellow). Source: adapted from Ishigami et al., 2017 [303].
2.6.2. Assembly
CIV assembly is now understood as a modular process. MTCO1 was classically
considered the “seed” around which the rest of the complex assembles [304,305]. However,
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recent evidence indicates that the first CIV subassembly is formed by the association
between two nuclear-encoded subunits, COX4I1 and COX5A [306]. This module contains
also HIGD1A, a protein initially proposed to be involved in the regulation of CIV activity
during hypoxia [307].
In parallel, the MTCO1 module, also known as “MITRAC” (MItochondrial TRans-
lation Regulation Assembly intermediate of Cytochrome c oxidase) [308,309], is formed,
composed of the CIV subunit and a series of assembly factors necessary for its matura-
tion and stabilization. The first level of regulation of this module is translational, with
the activity of the mitochondrial RNA-binding protein LRPPRC [310] and the transla-
tional activator TACO1 [311]. After translation, the newly synthesized protein has to
be inserted in the IMM. The first factors binding MTCO1 are COX14/C12ORF62 and
COA3/CCDC56/MITRAC12 [308,312–314]. These two chaperones assist MTCO1 during
and after its insertion in the membrane and avoid the aggregation of MTCO1 subunits.
The transient complex MTCO1/COX14/COA3 is stabilized by another assembly factor,
CMC1 [315].
At this point of the pathway, MTCO1 needs the incorporation of the three prosthetic
groups. Heme a biosynthesis is carried out by COX10 and COX15 catalyzing the conversion
of heme b to heme o, and then heme o to heme a [316,317]. On the other hand, the assembly
factor SURF1 has been proposed to participate in its delivery [305]. In addition, PET117
might also have a role in this process because it was found interacting with COX15 in yeast,
but its involvement still has to be shown in mammals [318]. CuB incorporation is mediated
by the metallochaperone COX11 [319], which is maintained in the correct redox state by
COX19 [320]. The coppers are donated by COX17 [321].
MTCO2 requires binding with COX18 in order to be inserted in the IMM [322] and
with COX20/FAM36A and TMEM177 for stabilization [323,324]. Secondly, the CuA center
must be inserted in MTCO2. This process is regulated by the copper-binding proteins
COX17, SCO1 and SCO2 [325–327], together with COA6 [328,329] and COX16 [330,331].
The MTCO2 module (MTCO2 + COX5B + COX6C + COX7C + COX8A and, most proba-
bly, COX7B) is incorporated in intermediate steps of the assembly process by joining the
COX4I1-COX5A and the MTCO1 modules, forming the “S3” intermediary. This interme-
diary binds three assembly factors, PET100 [332], PET117 [318] and MR-1S [306]. MR-1S
is a vertebrate-specific chaperone that interacts with the highly conserved factors PET100
and PET117. An additional assembly factor, APOPT1 or COA8, was proposed to have a
role in the intermediate steps of CIV assembly in mouse and human mitochondria (Signes
et al., 2019). Finally, the MTCO3 module (MTCO3 + COX6A1 + COX6B1 + COX7A2) is
incorporated [306], followed by NDUFA4 initially described as a CI subunit and later
assigned to CIV [305]. All known CIV assembly factors are summarized in Table 6.







RNA stability and translation
- TACO1 Translational activator of mitochondria-encoded MTCO1. MTCO1-translation [311]
- LRPPRC Mitochondrial mRNA stability. - [310]
- FASTKD2 Involved in post-transcriptional RNA maturation, ribosome biogenesis andtranslation. - [333]
Heme a biosynthesis and insertion
Cox10 COX10 Heme a synthesis (conversion of heme b into heme o). MTCO1 module [316,334]
Cox15 COX15 Heme a synthesis (conversion of heme o into heme a). MTCO1 module [335,336]
Shy1 SURF1 Involved in the insertion or stabilization of heme a3.
Early MTCO1
subcomplexes [337]
Copper metabolism and insertion
Coa6 COA6 Copper homeostasis and transport to CIV. MTCO2 module [328,338]
Sco1 SCO1 Incorporation of copper atoms. MTCO2 module [327,339]
- SCO2 Incorporation of copper atoms. MTCO2 module [340]
Cox11 COX11 Copper chaperone. MTCO1 module [319,341]
Cox16 COX16 MTCO2 maturation. MTCO2 module [331,342]
Cox17 COX17 Copper transfer. MTCO1 module [321]








Cox19 COX19 Stabilization of COX11. MTCO1 module [320,343]
Assembly
Coa3 COA3/MITRAC12 Required for MTCO1 stability and assembly. Involved in translational regulationof MTCO1 and prevention of MTCO1 aggregation before assembly. MTCO1 module [313,314]
- COA7 Unknown. Unknown [177]
Cox14 COX14/c12orf62 MTCO1 stability and assembly; avoids MTCO1 aggregation. MTCO1 module [312,344]
Cmc1 CMC1 Stabilizes the interaction between MTCO1, COX14 and COA3. MTCO1 module [315]
- COX20/FAM36A MTCO2 chaperone for copper metalation. MTCO2 module [345]
Pet100 PET100 Assembly factor. S3 intermediary [346–348]
Pet117 PET117 Assembly factor; possible role in Cox15 oligomerization and function. S3 intermediary [318,349,350]
- MR-1S Interacts with PET117 and PET100. S3 intermediary [306]
- APOPT1/COA8 Intermediate assembly steps. Putative role in CIV protection from ROS damage. Unknown [351]
Cox18 COX18 Promotes the translocation of MTCO2 globular domain through the IMM. MTCO2 [352,353]
2.6.3. Pathologies Associated with Complex IV Deficiency
After CI-related pathologies, defects in CIV are the most common OXPHOS defects
associated with mitochondrial disease [193]. The most frequent clinical phenotypes asso-
ciated with CIV deficiencies are myopathy, affecting the skeletal muscles, and systemic
pathologies, such as Leigh’s disease and multiorgan failure (https://rarediseases.org/
rare-diseases/cytochrome-c-oxidase-deficiency/). As in most of the mitochondrial dis-
eases, symptoms can be very heterogeneous and the severity of the pathology can vary
greatly [354]. While most of the pathological mutations found in patients are associated
with assembly factors of the enzyme or with mitochondrial tRNAs (mutations in tRNALys,
tRNAAla, mt-tRNAPhe, tRNALeu, tRNATrp, tRNAAsp and tRNAGlu were found associated
with COX deficiency [354], only few cases of mutations in CIV structural subunits have
been reported. This observation suggests that mutations in CIV subunits might be incom-
patible with life. The genes found mutated in patients with CIV deficiency and the relative
clinical phenotypes are summarized in Table 7.
Table 7. CIV subunits and assembly factors associated with mitochondrial diseases.
Gene/Protein OMIM Associated Phenotype Reference
Complex IV subunits
MTCO1 516030 MELAS syndrome, myopathy, myoglobinuria, motor neurone disease, exercise intolerance, epilepsy,multisystem disorders, deafness, LHON or mitochondrial sensorineural hearing loss. [355–359]
MTCO2 516040 Encephalomyopathy, LHON, myopathy, hypertrophic cardiomyopathy. [360–363]
MTCO3 516050 MIDD, LHON, myopathy, Leigh disease, myoglobinuria, sporadic bilateral optic neuropathy,rhabdomyolysis, encephalopathy. [364–369]
COX4I1 123864 Short stature, poor weight gain, mild dysmorphic features, Fanconi anemia. [370]
COX4I2 607976 Exocrine pancreatic insufficiency, dyserythropoietic anemia, calvarial hyperostosis. [371]
COX5A 603773 Early-onset pulmonary arterial hypertension, lactic acidemia, failure to thrive. [372]
COX6A1 602072 Charcot–Marie–Tooth disease. [373]
COX6A2 602009 Muscle weakness and hypotonia, cardiomyopathy. [374]
COX6B1 124089 Severe infantile encephalomyopathy. [375]
COX7A1 123995 Failure to thrive, encephalopathy, hypotonia. [376]
COX7B 300885 Microphthalmia with linear skin lesions. [377]
COX8A 123870 Leigh-like syndrome presenting with leukodystrophy and severe epilepsy. [378]
NDUFA4 603833 Leigh syndrome. [298]
Complex IV assembly factors
SURF1 185620 Leigh syndrome, Charcot–Marie–Tooth disease. [379,380]
COA3/MITRAC12 614775 Mild phenotype, exercise intolerance, peripheral neuropathy, obesity and short stature. [308]
COA7 615623 Ataxia and peripheral neuropathy, cognitive impairments, leukodystrophy. [177]
COX14/c12orf62 614478 Severe lactic acidosis and dysmorphic features. [344]
COX20/FAM36A 614698 Growth delay, hypotonia, cerebellar ataxia. [381]
PET100 614770 Early-onset psychomotor delay, seizures, hypotonia, Leigh syndrome. [347,348]
PET117 614771 Neurodevelopmental regression. [350]
APOPT1/COA8 616003 Leukodystrophy, neurological signs. [382]
SCO1/SCO2 603644/604272 Cardioencephalomyopathy, Leigh syndrome-like symptoms, spinal muscular atrophy-like presentations,Charcot–Marie–Tooth disease type 4. [383,384]
COX10/COX15 602125/603646 Leigh syndrome, encephalopathy, cardiomyopathy, sensorineural deafness and metabolic acidosis. [316,336]
COA6/C1orf31 614772 Fatal infantile cardioencephalopathy. [385]
TACO1 612958 Leigh syndrome. [311]
COA5 613920 Fatal infantile cardioencephalomyopathy. [386]
FASTKD2 612322 Brain atrophy, epilepsy, delayed psychomotor development, bilateral optic atrophy, spastic hemiparesis,cardiomyopathy. [387,388]
LRPPRC 607544 French Canadian type of Leigh syndrome. [389]
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2.7. Complex V
2.7.1. Structure and Assembly
ATP synthase (Complex V, CV) is the enzyme that catalyzes the synthesis of ATP from
ADP and phosphate. It is composed of two distinct domains: the F1 domain, which faces
the mitochondrial matrix, and the Fo domain, located in the IMM [390,391]. The human
CV is composed of 29 proteins of 18 kinds, only two of which are encoded by the mtDNA
(ATP6 and ATP8) [392]. A schematic representation of the main domains of CV is shown in
Figure 13. The F1 domain is composed of three copies of subunits α and β, and one copy
of subunits γ, δ and ε. γ, δ and ε subunits form the central stalk of the complex, while α
and β are the subunits that physically interact with the ADP and ATP molecules [390]. Fo,
instead, is composed of a ring of c subunits and one copy each of subunits a, b, d, F6 and the
oligomycin sensitivity-conferring protein (OSCP). The c-ring stoichiometry is not constant,
but can vary, ranging from 8 copies in vertebrates to 15 in photosynthetic organisms [393].
Figure 13. Representation of S. cerevisiae CV structure. The main subunits of the enzyme are indicated
and shown in different colors. Source: adapted from Kuhlbrandt, 2019 [394].
Each c subunit is able to bind one proton in the IMS, which interacts with a conserved
carboxylate group from a glutamate or aspartate side chain. The protonation of these
subunits provokes the rotation of the c-ring, until the final dissociation of the proton at
the matrix side favored by the positive charge on a conserved arginine residue (A210) of
subunit a [56]. The c-ring is structurally linked to the γ and ε subunits and its rotation
provokes the turn of these subunits inside the α3β3 hexamer unit of F1. On the external side,
the α3β3 hexamer is prevented from rotating by the peripheral stalk formed by the two b
chains and the d subunit. The result of the proton transport, therefore, is first the rotation
of the c-ring, followed by the rotation of the γ subunit, and the consequent synthesis of
ATP through the binding change mechanism of α3β3. The binding change mechanism is
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based on the fact that the interactions between the γ subunit and the three β subunits are
not identical. The result is three different conformations for the three β subunits: T (tight),
L (loose) and O (open). The subunit in T conformation binds ATP very strongly and its
affinity for the molecule is so high that it will induce the conversion of ADP + Pi into ATP.
The subunit in the L conformation, instead, is able to bind ADP and Pi but it cannot release
the nucleotides. Finally, the O conformation allows the release of the formed ATP. The
result of the γ subunit rotation is the change in these subunit conformations allowing the
passage through all the stages and the generation of ATP [56].
As for the other complexes described, the CV assembly is also modular. Three sub-
assemblies are formed individually and then put together: the F1 module, the c-ring
and the peripheral stalk [395]. The F1 subcomplex formation requires the activity of
the chaperones ATPAF1/ATP11 and ATPAF2/ATP12, which bind ATP5B and ATP5A1,
respectively [396]. Initially, the F1 and the c-ring modules assemble. The peripheral stalk,
instead, is incorporated in two additional steps: the incorporation of b/ATP5F1, d/ATPH,
F6/ATP5J and OSCP/ATP5O first and the addition of e/ATP5I, g/ATP5L and f/ATPJ2
in a second step [397,398]. Different assembly factors involved in this process have been
identified in yeasts. Atp25 stimulates the synthesis and assembly of subunit c of the c-
ring [399], while the protease Atp23 processes and stabilizes the membrane-inserted yeast
Atp6, unprocessed in mammals [400]. Finally, the inner membrane assembly complex
(INAC), composed of Ina17 and Ina22 [401], binds and stabilizes two distinct assembly
intermediates of the yeast ATP synthase: the newly assembled c-ring and an assembly
intermediate composed of the F1 domain and the peripheral stalk.
2.7.2. Pathologies Associated with Complex V Deficiency
Patients presenting with CV defects are rare and generally associated with neonatal-
onset hypotonia and hypertrophic cardiomyopathy, lactic acidosis and 3-methylglutaconic
aciduria [193]. Only few pathological mutations in CV subunits or assembly factors have
been found in patients so far. The majority of these mutations were identified in MT-ATP6,
responsible for neurogenic muscle weakness and ataxia and retinitis pigmentosa (NARP)
syndrome [402,403], and MT-ATP8 [404], while rarer cases were found in ATP5E, ATP5A1,
ATPAF2 and TMEM70 [404–409]. The CV subunits or assembly factors found mutated in
patients with CV deficiency and the relative clinical phenotypes are summarized in Table 8.
Table 8. CV subunits and assembly factors associated with mitochondrial diseases.
Gene/Protein OMIM Associated Phenotype Reference
MT-ATP6 516060 Neuropathy, ataxia and retinitis pigmentosa (NARP), maternally inheritedLeigh’s syndrome (MILS), mental retardation, ataxia, cardiomyopathy. [402,403,410,411]
MT-ATP8 516070 Hypertrophic cardiomyopathy and neuropathy. [404]
ATP5E 614053 Neonatal-onset lactic acidosis, 3-methylglutaconic aciduria, mentalretardation, hypertrophic cardiomyopathy and peripheral neuropathy. [405]
ATP5A1 615228 Fatal infantile encephalopathy. [408]
ATPAF2 608918 Degenerative encephalopathy, elevated lactate levels, developmental delay. [412]
ATP5F1A 164360 Fatal infantile mitochondrial encephalopathy [408,413]
ATP5F1D 603150 Metabolic decompensation with lactic acidosis, hypoglycemia,hyperammonemia, 3-methylglutaconic aciduria, encephalopathy. [414]
ATP5F1E 606153 Neonatal-onset lactic acidosis, 3-methylglutaconic aciduria, mild mentalretardation, hypertrophic cardiomyopathy, peripheral neuropathy. [405]
TMEM70 612418 Neonatal mitochondrial encephalocardiomyopathy. [119]
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2.8. Localization of the OXPHOS Machinery in the IMM
The OXPHOS machinery is embedded in the IMM, together with a variety of other
mitochondrial proteins. Indeed, the IMM is one of the most protein-rich lipid bilayers in
biological systems, with a protein/lipid mass ratio of ~75:25 [415]. Many protein complexes
which localize in this compartment are not distributed randomly, but tend to cluster in
specific regions, according to their individual function. As discussed previously, the IMM
can be divided into two subdomains: the inner boundary membrane (IBM), opposite to the
OMM, and the cristae membrane (CM), the alias for invaginations of the membrane in the
matrix, connected by the cristae junctions.
Results obtained with quantitative immunogold-EM on mammalian mitochondria and
yeast cells demonstrated that the preferential location of OXPHOS complexes is the CM, but
that both subcompartments are dynamic and the distribution of mitochondrial proteins can
change according to the physiological state of the cell [416,417]. In particular, it has been
observed that OXPHOS enzymes—or intermediates of them—might localize in different
regions of the membrane in different stages of maturation. With the only exception of CII,
the respiratory chain enzymes are composed of both nuclear- and mitochondrial-encoded
subunits, and their biogenesis is the result of the coordination between two temporally
and spatially separated protein synthesis machineries. Consequently, it was proposed
that, while proteins synthesized in the matrix are translated and inserted directly in the
cristae, subunits that must be imported from the cytosol are preferentially inserted in the
IBM [417]. More recent analyses by super-resolution microscopy and quantitative cryo-
immunogold-EM have helped to determine where specifically CIII, CIV and CV subunits
are translated and inserted in the yeast inner membrane [418]. This study confirmed that,
under steady-state conditions, the mature forms of CIII, CIV and CV localize mainly in the
CM, while early stages of assembly are more enriched in the IBM. Indeed, mitoribosomes
translating COB mRNA (the very first step of CIII assembly) and Cbp3 and Cbp6 (markers
for the early assembly of the enzyme) were found more present in the IBM, while Cbp4
(a marker of the early-to-mid-assembly phase) was already less enriched in this subcom-
partment. Conversely, the integration of the Rieske protein, the last step of maturation,
which takes place after CIII dimerization, happened predominantly in the CM. Similarly,
Stoldt and colleagues investigated the localization of markers of the early (Pnt1, Cox18,
Coa1 and Cox20) and the late (Pet100) phases of CIV assembly, finding the earliest stages
of maturation enriched in the IBM and the late phases in the CM. By contrast, the entire
assembly pathway of CV seems to occur mainly in the CM [418].
2.9. Supercomplexes
The picture of the OXPHOS machinery as individual enzymes sitting in the IMM is a
simplified vision of what happens in the mitochondria of living cells. A second level of
complexity is added by the formation of supercomplexes (SC), stable structures composed
of the association of the respiratory chain enzymes.
The development of blue native PAGE techniques [419] allowed the separation and
detection of both the individual complexes and the supercomplexes, composed of different
combinations of CI, CIII2 and CIV. However, many questions remained open in the field.
Firstly, it was necessary to characterize the type and strength of these inter-complex
interactions, in order to hypothesize a realistic model of IMM organization. Secondly,
it was necessary to attempt to explain the biological and physiological function of these
structures. This second aspect will be one of the central questions of this thesis.
2.9.1. Existing Models
The models to explain the organization of the respiratory chain enzymes have changed
over time. The first proposal, known as the “fluid state” model, describes the mitochondrial
complexes as individual and independent units that float in the inner membrane and collide
randomly with each other, allowing the passage of electrons. According to this theory,
cytochrome c would be diffusing in three dimensions, in order to transport electrons
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between complexes, and this transient and casual formation of each SC species by collision
would allow the cell to adapt to different energy demands. This model was the most
accepted one during the 1980s, following the presentation of the random collision model of
Hackenbrock [420]. The fluid model is supported by the very high protein-to-lipid ratio
in the membrane, which allows the frequent interaction of the enzymes, and by scanning
calorimetry [421] and freeze-fracture electron microscopy [422] studies showing that the
intramembrane particles are randomly distributed in the IMM. Moreover, independent
studies showed that CoQ is a mobile carrier [423,424], confirming an essential part of this
theory. On the other hand, however, both blue native PAGE and electron microscopy
experiments in different systems, such as mammals, bacteria, yeasts and plants, suggest
more stable interactions between these particles [425–429]. In the original experiments,
it was necessary to solubilize the membranes with a strong detergent in order to isolate
the single enzyme, while milder detergents such as digitonin used in blue native studies
preserve the various species of SC intact.
The second and opposite model proposed was the “solid state” model, which sup-
ported the vision that the different activities and redox centers were contained in an
undissociated protein matrix. These structures were also thought to contain Q and cyt
c [430,431]. This view, however, was challenged by the observation that the isolated com-
plexes were functional and that they could diffuse within the lipid bilayer, as well as
activity rate values being compatible with a mechanism of random collision [432]. The
“solid state” model remained the most accepted view until the development of the native
electrophoretic techniques described above, which showed the co-existence of supercom-
plexes of different sizes and the individual respiratory chain complexes. From a functional
point of view, the proximity of the enzymes and the molecular carriers involved would
increase the interactions and prevent the intermediates from escaping or being sequestered
by other enzymes for use in secondary metabolic pathways [433]. Indeed, in the model in
which the different supramolecular species coexist and trap the mobile electron carriers,
the association of CI, III and IV and, on the other side, CIII and IV would define two
different functional CoQ populations: CoQ dedicated to transferring electrons originating
from NADH (CoQNADH), which is trapped in SC containing CI, and free CoQ in the inner
mitochondrial membrane for use by CII and other enzymes that use FAD (CoQFAD) [434].
However, this system is not compatible with the kinetics of the CoQ pool, and recent
additional studies indicated that cytochrome c diffuses freely in the IMS in yeast [433] and
that only one CoQ and cytochrome c pools are present, accessible to all the enzymes [435].
An additional interesting analysis has been proposed after inserting AOX (an alternative
oxidase) in vitro, a cyanide-insensitive quinol oxidase originally from Trypanosoma brucei,
in bovine heart mitochondria [436]. AOX receives electrons from ubiquinone, bypassing
CIII and CIV. In the case of two separate pools of ubiquinone, the “respirasome pool”
should continue to provide a substantial flux of electrons through the supercomplex. In-
stead, a competition between respirasomes and AOX was observed in increasing the AOX
supplement, confirming the theory that ubiquinone is not channeled but can move freely
in the IMM.
In conclusion, putting together the information available today, the most realistic
proposal is a middle-ground and more dynamic model in which various species of super-
complexes and free respiratory complexes coexist. For now, the model that explains this
phenomenon is the so-called “dynamic aggregate” or “plasticity” model, which proposes
a dynamic interchange of the complexes in their “free” and associated states into SC in
response to varying energetic demands. A premise for the model is that the complexes are
pre-assembled individually before associating with each other [437,438].
2.9.2. Species of Supercomplexes and Complex–Complex Interactions
Structures of the I1III2IV and I1III2 SC from mammals and plants have been resolved
by single-particle electron cryo-EM [439–442] and by electron cryo-tomography (cryo-
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ET) [443,444]. The yeast Saccharomyces cerevisiae lacks CI, and complexes III and IV form two
SC species III2IV1 and III2IV2, the structures of which have been recently solved [445,446].
In mammals, the main supercomplex species are III2IV1, I1III2 and the respirasomes
I1III2IV1−n. The existence of a “Megacomplex” with a I2III2IV2 stoichiometry, which might
also bind CII, was reported in cultured human cells [441]. Additionally, CIV and CV can
form homodimers and CIV is involved in the formation of other high-molecular weight
structures not yet identified, but visible in blue native PAGE experiments [395,447,448].
“Megacomplexes” containing also CII have been proposed as well, but their existence
is debated.
Since Saccharomyces cerevisiae lacks CI [449], yeast-based studies of the respirasomes
have been conducted in Yarrowia lipolytica [444]. In this model, CI and CIII interactions
are comparable to what has been observed in mammals, while CIV was found in various
positions around CIII2, but not in the position most commonly observed in the porcine
heart respirasomes, contacting the ND5 module of CI (Figure 14).
In plants, on the other hand, CIV was never observed in the respirasomes and the
only apparent supercomplex was I1III2. Interestingly, supercomplexes are not universal
and simpler organisms such as Escherichia coli, which express CI, CII and CV homologues,
but not CIII, do not present such structures [450]. In these bacteria, the different complexes
have been shown to not co-localize together and to not sub-localize in specific domains
over the membrane surface [451].
Figure 14. Overall structure of porcine respirasome (I1III2IV1). Source: adapted from Milenkovic
et al., 2017 [452].
Interestingly, the percentage of free complexes vs. SC varies largely between different
species. In bovine heart mitochondria, electron cryo-tomography indicated that only 56% of
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CI was associated with other complexes [444]. However, BN-PAGE-based quantifications
of the same cell type estimated that only 14–16% of free CI was present [426]. On the other
hand, blue native-PAGE experiments using human mitochondria show a minimal part of
CI (~10% at the most, in the presence of digitonin) migrating as an individual complex [453].
In any case, there seems to be more of “free” CI in mitochondria from different tissues
in mammalian organisms such as sheep, pigs or mice than in humans [437,454]. These
differences might be due to various reasons, including artefacts introduced during the
sample preparation or actual differences in the regulation of energy demands between
different organisms.
In addition, in the same organism, not all the complexes engage in the formation of
SC in the same proportion. Indeed, in humans, it has been estimated that while 85%–100%
of CI is inserted in a supercomplex structure, only 55%–65% of CIII and 15%–25% of CIV
are found in SC [426,453,455,456].
Structural analyses have also been important to define which subunits are involved in
the complex–complex interaction. The association between CI and CIV seems to involve
subunit COX7A of CIV, and ND5 and NDUFA9 of CI (Letts et al., 2016). COX7A, together
with COX8B, could be involved also in the interaction with CIII, through binding of
UQCRC1, UQCRQ, UQCR10 or UQCR11 (Letts et al., 2016) [440,444]. Concerning the
connection between CI and CIII, subunit NDUFA11 of CI seems to face and contact the
transmembrane region of CIII, close to UQCRB and UQCRQ [440] (Letts et al., 2016).
Other CI subunits that might be involved in the interaction are NDUFAB1 and NDUFB9,
contacting UQCRC1 of CIII.
2.9.3. Possible Functional Roles of Supercomplexes
The biological function of SC is still highly debated and various hypotheses have been
proposed. The first theory proposes that their role is substrate channeling, increasing OX-
PHOS efficiency due to the physical proximity of all the machinery components [457]. The
second possible function of SC might be to minimize ROS production. ROS are generated
by the reduction of oxygen by electrons leaked from the ETC and are physiologically used
as a signaling molecule [458]. However, if there is an imbalance between the excessive
formation of ROS and limited antioxidant defenses, ROS can become deleterious and
damage mtDNA, lipids and proteins. In this case, the formation of supra-structures might
decrease electron or proton leakages during respiration. This theory is supported by two
studies. In the first one, ROS production by CI has been shown to increase in two experi-
mental conditions that inhibit the formation of CI and CIII interactions: treating bovine
heart mitochondria or liposome-reconstituted supercomplex I-III with dodecyl maltoside,
and reconstructing CI and CIII at a high phospholipid/protein ratio [459]. In the second
study, the difference in SC formation in astrocytes and neurons was analyzed, showing
how astrocytes, which present a higher percentage of free CI, are characterized by poorer
mitochondrial respiration but higher ROS production [460].
The last hypothesis, which will be the basis of the first project presented in this thesis,
is that the formation of SC is necessary for the assembly and/or stability of the single
enzymes. This theory is supported by the observation that defects in one enzyme can lead to
multi-complex deficiencies. Indeed, mutations in MTCYB, fundamental for CIII assembly,
also induce CI deficiencies [461–463]. Similarly, patients presenting with mutations in
CIII assembly factors, such as BCS1L, can display defects in both CI and CIV [464], while
the suppression of CIV in mouse fibroblasts affects CI assembly or stability [465]. An
explanation for this phenomenon was that CI was destabilized after its complete assembly
by an active oxidative stress-triggered degradation [466–468]. However, a multistep model
for SC assembly that sees CI intermediates binding CIII and CIV subunits before the
completion of the mature enzyme was proposed [469]. In the same study, UQCRFS1 was
shown to insert preferentially within the III2 + IV supercomplex, instead of dimeric CIII2.
Finally, an additional role of SC is reserved to the ATP synthase. CV does not seem
to interact with the rest of the respiratory chain, but it is able to form dimers and more
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complex supra-structures such as tetramers and hexamers [470]. These supercomplexes
localize specifically at the bottom of the cristae, where they appear to enforce a strong local
curvature on the inner membrane, necessary for the formation of the invagination [471].
2.9.4. Assembly of Supercomplexes
Being that the assembly of the monomeric forms of the OXPHOS enzymes requires
the participation of a number of assembly factors, it has been proposed that additional
proteins should be involved in the formation of supercomplexes.
The first proposed assembly factor was COX7A2L or SCAF1 (supercomplex assembly
factor 1), an isoform of the CIV subunit COX7A, described originally to have a role in
the inclusion of CIV in III2 + IV and I + III2 + IV1–4 [434]. However, following studies
showed that the lack of COX7A2L affects the formation of the SC III2 + IV, but not of
respirasomes [453,472–474]. Pérez-Pérez data also showed how COX7A2L binds to CIII2
early during its assembly, indicating a preferential interaction with this complex [472].
Thus, it might possess a role in the establishment of a checkpoint for the regulation of CIII2
levels and its incorporation into SC [453].
Another study showed how the incorporation of different COX7A isoforms might
determine which CIV-containing species (monomer, dimer or respirasome) is formed [13].
Thus, the CIV subunit COX7A2 is replaced by COX7A2L in supercomplexes with both
CIV and CIII, and by COX7A1 in CIV dimers. Moreover, other CIV tissue-specific subunit
isoforms might play a role in this, as well as dimers, which appeared to be stabilized by
the COX6A2 isoform rather than COX6A1. COX6A subunits are localized at the interface
between the two monomers, a position that would favor the regulation of the dimerization.
COX7A2 and COX6A1, instead, would favor the free CIV form.
Analyses conducted in Saccharomyces cerevisiae suggested the participation of Rcf1 and
Rcf2 in the formation of respirasomes [448]. In yeast, the loss of Rcf1 affects CIV function
and the correct insertion of Cox13 (equivalent to human COX6A). These data showed
also deficiency in SC formation, but recent reports point to this being an indirect effect
due to CIV defects [475–477]. While Rcf2 is specific to yeast, two orthologs of Rcf1 have
been identified in humans: RCF1a/HIGD1A and RCF1b/HIGD2A. HIGD1A has been
confirmed to bind CIV and it has been suggested to affect the interaction between CIV
and cytochrome c, or to act in a still unclear way on the heme centers [306,307]. Another
study found HIGD1A directly involved in CIII biogenesis, promoting the final incorpo-
ration of UQCRFS1, and suggested its participation in the formation of CIII-containing
SC [478]. Concerning HIGD2A, instead, two independent groups demonstrated that the
knockdown of this protein leads to impaired SC formation by the release of CIV from
respirasomes [479,480]. However, HIGD2A was identified as a MTCO3 module assembly
factor and it is possible that its impact on SC is a pleotropic effect due to impaired CIV
biogenesis [478,481].
Concerning oligomerization of CV, the role of post-translational modifications in Atp20
has been investigated [482]. Specifically, the molecular mechanism seems to revolve around
the phosphorylation of serine 62, which inhibits the dimerization of the ATP synthase.
Finally, also the lipid composition of the IMM and, in particular, the level of cardiolipin
are important for the stabilization of SC. In yeast lacking Taz1, the acyltransferases involved
in the remodeling of cardiolipin and CIII and CIV associations are destabilized [483]. In
Barth syndrome patients, harboring mutations in Tafazzin (the human ortholog of Taz1),
the assembly and stability of CIV and its SC forms are affected, with a secondary effect also
on CI + III associations [484].
2.9.5. Conclusive Remarks
Mitochondria fulfil a variety of functions in the cell, including the well-known energy
production via oxidative phosphorylation. For this reason, the failure of mitochondria to
operate correctly is associated with a wide spectrum of genetic disorders. In this review,
we have analyzed, in detail, the structure, the assembly pathway and the organization in
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supercomplexes of each component of the OXPHOS machinery and how defects in these
enzymes are linked to diseases in humans.
Our review aimed to show the heterogeneity and the complexity behind the still grow-
ing group of pathologies normally identified as “mitochondrial diseases”, the pathophysi-
ology of which is still often poorly understood. During the past decade, big advancements
in genetic screening and in the study of mitochondrial biology and physiology have been
made. However, the diagnosis of mitochondrial disorders is limited to about half of the
suspected cases, the genotype–phenotype correlation is not always comprehended and
effective therapies are still missing.
Future research will need to continue investigating the biology of this organelle, in
order to better understand the molecular and cellular basis of mitochondrial diseases, and
identify possible targets for new treatments.
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